IN2014DN08067A - - Google Patents

Info

Publication number
IN2014DN08067A
IN2014DN08067A IN8067DEN2014A IN2014DN08067A IN 2014DN08067 A IN2014DN08067 A IN 2014DN08067A IN 8067DEN2014 A IN8067DEN2014 A IN 8067DEN2014A IN 2014DN08067 A IN2014DN08067 A IN 2014DN08067A
Authority
IN
India
Prior art keywords
acne
outbreaks
antiseptic
composition
skin
Prior art date
Application number
Inventor
Borunda Juan Socorro Armendáriz
Castro José Agustín Rogelio Magaña
Santoyo Pedro Peña
Cervantes Laura Vázquez
Original Assignee
Cell Therapy And Technology S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Technology S A De C V filed Critical Cell Therapy And Technology S A De C V
Publication of IN2014DN08067A publication Critical patent/IN2014DN08067A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a semi solid topical composition which contains pirfenidone and an anti microbial/antiseptic such as modified diallyl disulphide oxide (M-DDO) and to the method for manufacturing same which has advantages over other pharmaceutical forms for cutaneous delivery known in the prior art which can be used as an anti fibrotic anti inflammatory and antiseptic agent in the prevention treatment and reversal of acne and post acne lesions. Said composition can also be used to reduce the redness of the skin to halt the formation of new outbreaks of acne to reverse existing outbreaks and to regenerate skin damaged by acne.
IN8067DEN2014 2012-03-28 2013-02-27 IN2014DN08067A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2012003694A MX346763B (en) 2012-03-28 2012-03-28 SEMISOLID TOPIC COMPOSITION CONTAINING PYRFENIDONE AND DIALYL MODIFIED DISULFIDE OXIDE (ODD-M) TO ELIMINATE OR PREVENT ACNE.
PCT/MX2013/000027 WO2013147577A1 (en) 2012-03-28 2013-02-27 Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne

Publications (1)

Publication Number Publication Date
IN2014DN08067A true IN2014DN08067A (en) 2015-05-01

Family

ID=48096131

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8067DEN2014 IN2014DN08067A (en) 2012-03-28 2013-02-27

Country Status (22)

Country Link
US (7) US20150148382A1 (en)
EP (1) EP2832354A1 (en)
JP (1) JP2015513359A (en)
KR (1) KR20140146144A (en)
CN (1) CN104334171A (en)
AR (1) AR090457A1 (en)
AU (1) AU2013240709A1 (en)
CA (1) CA2868729C (en)
CL (1) CL2014002591A1 (en)
CO (1) CO7071140A2 (en)
CU (1) CU20140114A7 (en)
DO (1) DOP2014000218A (en)
EA (1) EA201401031A1 (en)
IL (1) IL234816A0 (en)
IN (1) IN2014DN08067A (en)
MA (1) MA20150062A1 (en)
MX (1) MX346763B (en)
PH (1) PH12014502154A1 (en)
SG (1) SG11201406035VA (en)
TN (1) TN2014000396A1 (en)
UY (1) UY34700A (en)
WO (1) WO2013147577A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
MX2011007675A (en) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans.
MX346763B (en) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V SEMISOLID TOPIC COMPOSITION CONTAINING PYRFENIDONE AND DIALYL MODIFIED DISULFIDE OXIDE (ODD-M) TO ELIMINATE OR PREVENT ACNE.
MX356551B (en) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne.
CN106459042B (en) 2014-04-02 2019-06-28 英特穆恩公司 Antifibrotic pyridones
CN106491517B (en) * 2016-11-23 2019-12-06 佛山科学技术学院 Preparation method of pirfenidone PVA hydrogel and pirfenidone PVA hydrogel
US20180360751A1 (en) * 2017-06-19 2018-12-20 Advanced Fibrosis Research LLC Transdermal cream for treating Dupuytren's Contracture
MX366086B (en) * 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage.
MX368750B (en) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Oil based semisolid pharmaceutical compositions containing pirfenidone for application in tissue repair.
EP4003256B1 (en) 2019-07-30 2025-12-10 The Government of The United States, as Represented by The Secretary of The Army Layered composite for scar treatment and prevention

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
DE2362958C2 (en) 1972-12-18 1984-06-14 Affiliated Medical Research Inc., Princeton, N.J. Pharmaceutical composition used to relieve inflammation, fever or pain in mammals or to lower uric acid levels in blood serum
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
JPS51128433A (en) 1975-04-30 1976-11-09 Ajinomoto Co Inc A herbicide
SE430609B (en) 1976-12-21 1983-11-28 Sca Development Ab SET TO CELLULOUS DERIVATIVES MAKE ABSORBING MATERIAL
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
EP0702551B1 (en) 1993-05-07 2002-09-25 MARGOLIN, Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
HU227918B1 (en) 1995-12-21 2012-06-28 Pfizer Injectable quinolone formulations
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
DE69917248T2 (en) 1998-03-17 2005-05-04 Margolin, Solomon B., Dallas TOPICAL ANTISEPTIC COMPOSITIONS AND METHOD
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
EP1113798B1 (en) 1998-09-18 2003-01-02 Mepha AG Topical formulation of alkyl-, phenyl-pyridone
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
IN191090B (en) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
DE60234812D1 (en) 2001-01-29 2010-02-04 Shionogi & Co DRUG PROTEIN CONTAINING 5-METHYL-1-PHENYL-2- (1H) -PYRIDONE AS ACTIVE INGREDIENT
US20030103941A1 (en) 2001-10-09 2003-06-05 Crombleholme Timothy M. Materials and methods for preventing or reducing scar formation
CH696420A5 (en) 2002-09-13 2007-06-15 Mepha Ag New stable formulations of alkyl, phenyl-pyridones for topical use.
WO2004073713A1 (en) 2003-02-21 2004-09-02 Shionogi & Co., Ltd. Pirfenidone gel preparation
EP1596883A1 (en) 2003-02-28 2005-11-23 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004078194A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004089283A2 (en) 2003-04-04 2004-10-21 Intermune, Inc. Compositions and methods for treating viral infections
WO2005062739A2 (en) * 2003-05-23 2005-07-14 Ott David M S-allylmercaptocysteine prodrugs and methods of treatment
WO2005000227A2 (en) 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
RS20060259A (en) 2003-10-14 2008-08-07 Intermune Inc., Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20070258946A1 (en) 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
CN100542532C (en) 2004-05-24 2009-09-23 上海睿星基因技术有限公司 The purposes of pirfenidone in the medicine of preparation treatment hepatic injury necrosis and acute lung injury
US20060051339A1 (en) 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US20060115503A1 (en) 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
EP1928454B1 (en) 2005-05-10 2014-09-24 Intermune, Inc. Pyridone derivatives for modulating stress-activated protein kinase system
EA019888B1 (en) 2005-07-25 2014-07-30 Интермьюн, Инк. Intermediate compound for making macrocyclic inhibitors of hepatitis c virus replication and method of synthesis thereof
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
EP1960405A2 (en) 2005-11-23 2008-08-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
EP1973525B1 (en) 2005-12-05 2014-04-30 RBA Pharma Inc. Emulsion-containing medical articles
CN101088557A (en) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 Medicine composition for preventing and treating HIV infection and its application
CN101687789A (en) 2007-02-12 2010-03-31 因特蒙公司 Novel inhibitors hepatitis c virus replication
JP2010520194A (en) 2007-03-02 2010-06-10 ミロン、タリア Mercaptopurine derivatives as anticancer agents
US20080287508A1 (en) 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
CN101842355A (en) 2007-06-20 2010-09-22 奥斯拜客斯制药有限公司 Substituted N-arylpyridones as fibrosis inhibitors
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
US20090137354A1 (en) 2007-11-27 2009-05-28 Shimano Inc. Bicycle rear derailleur
CA2709151A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100256031A1 (en) 2008-10-10 2010-10-07 Jeffrey Wu Shine control cleanser
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AR075584A1 (en) 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
CN101972236A (en) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 Sustained release preparation containing pirfenidone
CN101972225A (en) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 Pirfenidone-contained gel composition
US10092552B2 (en) 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
ES2742273T3 (en) 2011-02-15 2020-02-13 Aclaris Therapeutics Inc Pharmaceutical oxymetazoline cream compositions to treat rosacea symptoms
CN102670600A (en) 2011-03-12 2012-09-19 赵海静 Medicinal product for inhibiting scar and promoting wound healing, and preparation method and application of medicinal product
CN102670632A (en) 2011-03-12 2012-09-19 赵海静 Medical application of pirfenidone in inhibition of skin scar formation
US9241921B2 (en) 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
MX2011007675A (en) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans.
CN102488660A (en) 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 Sustained-release pellet containing pirfeudone
MX346763B (en) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V SEMISOLID TOPIC COMPOSITION CONTAINING PYRFENIDONE AND DIALYL MODIFIED DISULFIDE OXIDE (ODD-M) TO ELIMINATE OR PREVENT ACNE.
WO2013181691A1 (en) 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
CA2875541A1 (en) 2012-06-12 2013-12-19 Patrick F. Smith Combination of therapeutic agents for treating hcv infection
MX356551B (en) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne.
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CN105188758A (en) 2013-03-15 2015-12-23 梅迪奇斯医药公司 Topical compositions of flunisolide and methods of treatment
MX352342B (en) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Process for the manufacture of improved benzethonium chloride-diallyl disulphide oxide modified complex, the obtained complex and uses thereof.
CN103550242B (en) 2013-11-22 2015-07-15 四川国康药业有限公司 Pharmaceutical composition for treating hepatic fibrosis and preparation method thereof
GB201508419D0 (en) 2015-05-15 2015-07-01 Cambridge Entpr Ltd Detection of T cell exhaustion or lack of T cell costimulation and uses thereof
HK1255224A1 (en) 2015-12-16 2019-08-09 Daiichi Sankyo Company, Limited Wound treatment agent
JOP20170113B1 (en) 2016-05-09 2023-03-28 Bayer Pharma AG Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones and use thereof
MX364040B (en) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V PHARMACEUTICAL USE OF A COMPOSITION CONTAINING PROLONGED RELEASE PIRFENIDONE (PFD-LP) FOR THE REVERSION AND TREATMENT OF HUMAN ESTEATOHEPATITIS (NAFLD / NASH).
TWI770157B (en) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX366086B (en) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V A semi-solid topical composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage.
MX368750B (en) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Oil based semisolid pharmaceutical compositions containing pirfenidone for application in tissue repair.

Also Published As

Publication number Publication date
EA201401031A1 (en) 2015-05-29
CL2014002591A1 (en) 2015-01-16
PH12014502154A1 (en) 2014-12-10
US11766426B2 (en) 2023-09-26
MX2012003694A (en) 2013-09-30
US20240216350A1 (en) 2024-07-04
DOP2014000218A (en) 2014-12-15
SG11201406035VA (en) 2014-11-27
IL234816A0 (en) 2014-12-31
US11013727B2 (en) 2021-05-25
CO7071140A2 (en) 2014-09-30
US9949959B2 (en) 2018-04-24
KR20140146144A (en) 2014-12-24
JP2015513359A (en) 2015-05-11
US20150148382A1 (en) 2015-05-28
US20250367177A1 (en) 2025-12-04
CA2868729A1 (en) 2013-10-03
CU20140114A7 (en) 2015-01-29
MX346763B (en) 2017-03-31
WO2013147577A1 (en) 2013-10-03
CN104334171A (en) 2015-02-04
AR090457A1 (en) 2014-11-12
US20200061040A1 (en) 2020-02-27
EP2832354A1 (en) 2015-02-04
US20180214434A1 (en) 2018-08-02
MA20150062A1 (en) 2015-02-27
US20160228424A1 (en) 2016-08-11
US20210346360A1 (en) 2021-11-11
TN2014000396A1 (en) 2015-12-21
CA2868729C (en) 2020-10-20
AU2013240709A1 (en) 2014-11-06
UY34700A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
IN2014DN08067A (en)
IN2015DN02573A (en)
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PH12015501108B1 (en) Treatment of pulmonary disease
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2015003360A3 (en) Therapeutically active compounds and their methods of use
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX2015003021A (en) Glycyrrhetinic acid derivatives with anti-inflammatory activity.
EA201491832A1 (en) METHOD OF HAIR TREATMENT
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2012050831A3 (en) Combination treatment for dermatological conditions
MX363993B (en) Pharmaceutical compositions with hydrating and lubricating activity.
MX2015001488A (en) Treating inflammation using serelaxin.
WO2014145236A3 (en) The use of sdf-1 to mitigate scar formation
MX2014014818A (en) Method for treating skin inflammatory diseases.
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
WO2012053014A3 (en) Method for treatment of acne using pharmaceutical compositions of clindamycin and adapalene
WO2009155070A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
GB201117490D0 (en) Anti-inflammatory compounds
WO2014070696A3 (en) Treatment of chronic dermal inflammatory with norketotifen
CA2866819C (en) Method for treating inflammation